Drug
Sorafenib clinical trials
Also written Nexavar, BAY 43-9006 and BAY 54-9085.
- studies test it
- 509
- open now
- 13
- in phase 3
- 47
- first study started
- 2002
Keep track of what changes. Save the Sorafenib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Nexavar
- 210
Development codes
- BAY 43-9006
- 116
Studies by the year they started
508 studies that test it; most in 2007 (75)
| Year | Studies |
|---|---|
| 2002 | 4 |
| 2003 | 1 |
| 2004 | 22 |
| 2005 | 44 |
| 2006 | 38 |
| 2007 | 75 |
| 2008 | 69 |
| 2009 | 62 |
| 2010 | 28 |
| 2011 | 35 |
| 2012 | 22 |
| 2013 | 19 |
| 2014 | 17 |
| 2015 | 20 |
| 2016 | 12 |
| 2017 | 10 |
| 2018 | 5 |
| 2019 | 4 |
| 2020 | 5 |
| 2021 | 4 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 196
- Phase 2
- 309
- Phase 3
- 47
- Phase 4
- 4
- No phase
- 18
What it is tested for
Each study’s main condition, where its own words name it.
- Melanoma
- 23
Who runs them
Industry 89 · Other 420
National Cancer Institute (NCI) (75) · Bayer (49) · M.D. Anderson Cancer Center (22) · SCRI Development Innovations, LLC (9) · Memorial Sloan Kettering Cancer Center (8) · University Health Network, Toronto (8) · St. Jude Children's Research Hospital (7) · H. Lee Moffitt Cancer Center and Research Institute (6)
Often tested with
Tested in the same studies.
Bevacizumab (26) · Gemcitabine (21) · Everolimus (19) · Cisplatin (19) · Erlotinib (17) · Paclitaxel (16) · Carboplatin (15) · Capecitabine (14)
Studies
Open first, then newest update. How each study uses Sorafenib is read from its arms, and is right about nine times in ten.
Testing it · 509
- Phase 2 Study of WGI-0301 for Advanced HCCRecruitingPhase 2Zhejiang Haichang Biotech Co., Ltd.NCT06309485Written as Sorafenib 400 mg PO, BID continuously
- Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatmentRecruitingPhase 2Centre Leon BerardNCT02029001Written as Sorafenib (400 mg BID)
- AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular CarcinomaRecruitingPhase 2University of FloridaNCT05669339Written as Sorafenib
- Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor PatientsRecruitingPhase 1/2St. Jude Children's Research HospitalNCT05468359Written as Sorafenib
- Efficacy and Safety of Sorafenib in New-Onset Type 1 Diabetes MellitusNot yet recruitingPhase 2Second Xiangya Hospital of Central South UniversityNCT06227221Written as Sorafenib
- Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical StudyNot yet recruitingPhase 2/3Nanfang Hospital, Southern Medical UniversityNCT07264010Written as Sorafenib (SORA)
- Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell TransplantationRecruitingPhase 2/3Ruijin HospitalNCT06972641Written as Sorafenib (BAY-43-9006),giritinib
- Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCCRecruitingPhase 2Humanity & Health Medical Group LimitedNCT03899428Written as Sorafenib
- Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid CancerRecruitingPhase 2West China HospitalNCT06482086Written as Sorafenib
- SNF Platform Study of HR+/ HER2-advanced Breast CancerRecruitingPhase 2Fudan UniversityNCT05594095Written as Sorafenib
- Sorafenib Relapase Prophylaxis After HCT With PTBCy RegimenRecruitingPhase 2St. Petersburg State Pavlov Medical UniversityNCT06532084Written as Sorafenib
- Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular CarcinomaRecruitingPhase 1/2Assiut UniversityNCT06527495Written as Sorafenib
- Treateament of Newly Diagnosed Acute Monocytic Leukemia in ChildrenRecruitingPhase 2/3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT05313958Written as Sorafenib
- Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular CancerCompletedPhase 2The University of Texas Health Science Center at San AntonioNCT03037437Written as Sorafenib (SOR)
- Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced CancerActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT01187199Written as Sorafenib
- Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory LeukemiaActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT03132454Written as Sorafenib
- Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS MutationCompletedPhase 1/2Institut du Cancer de Montpellier - Val d'AurelleNCT00989469Written as Nexavar (Sorafenib) and irinotecan (Campto)
- Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by SurgeryCompletedPhase 2Centre Oscar LambretNCT00874874Written as sorafenib tosylate
- Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or MelanomaActive, not recruitingPhase 1National Cancer Institute (NCI)NCT01303341Written as Sorafenib Tosylate
- Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid LeukemiaActive, not recruitingPhase 1National Cancer Institute (NCI)NCT01861314Written as Sorafenib Tosylate
See all 509 studies that test Sorafenib →
Given in every arm · 69 — Sorafenib is usual care beside what is tested
- Pediatric Precision Laboratory Advanced Neuroblastoma TherapyRecruitingPhase 2Giselle ShollerNCT02559778Written as sorafenib
- Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AMLRecruitingPhase 2Children's Hospital of Soochow UniversityNCT06221683Written as Sorafenib
- Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After SurgeryActive, not recruitingPhase 3Children's Oncology GroupNCT03533582Written as Sorafenib
- A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and BevacizumabActive, not recruitingPhase 3Hoffmann-La RocheNCT04770896Written as Sorafenib
- Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver CancerCompletedPhase 3National Cancer Institute (NCI)NCT01015833Written as Sorafenib Tosylate
- Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib AloneCompletedPhase 3SillaJen, Inc.NCT02562755Written as Sorafenib
- Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid CancerActive, not recruitingPhase 2Alliance for Clinical Trials in OncologyNCT02143726Written as sorafenib
- Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver CancerCompletedPhase 3Radiation Therapy Oncology GroupNCT01730937Written as Sorafenib
- Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain TumorsCompletedPhase 1Sidney Kimmel Cancer Center at Thomas Jefferson UniversityNCT00639262Written as Sorafenib
- First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver CancerActive, not recruitingPhase 1Mina Alpha LimitedNCT02716012Written as Sorafenib 200mg
- Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib AloneCompletedPhase 2Mina Alpha LimitedNCT04710641Written as Sorafenib
- Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC with Major Portal Vein Tumor ThrombosisCompletedPhase 2Peking UniversityNCT03009461Written as Sorafenib
- Sorafenib Chemoembolization Evaluation Controlled TrialCompletedPhase 3Air Force Military Medical University, ChinaNCT01906216Written as Sorafenib
- HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCCCompletedPhase 3Sun Yat-sen UniversityNCT02856126Written as Oral Sorafenib
- Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute LeukemiaCompletedPhase 2M.D. Anderson Cancer CenterNCT02135874Written as Sorafenib
- A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular CarcinomaCompletedPhase 1/2Sumitomo Pharma America, Inc.NCT02279719Written as Sorafenib
- TACE vs TACE+SBRT for Unresectable Hepatocellular CancerStatus unknownPhase 2/3Tata Memorial HospitalNCT02794337Written as Sorafenib
- Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver CancerCompletedPhase 1/2Alliance for Clinical Trials in OncologyNCT00867321Written as sorafenib tosylate
- Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube CancerCompletedPhase 2National Cancer Institute (NCI)NCT00096200Written as Sorafenib Tosylate
- Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib TreatmentStatus unknownPhase 4First Affiliated Hospital Xi'an Jiaotong UniversityNCT05113290Written as Sorafenib
Showing 20 of 69.
As the comparator · 55 — what is tested is compared with Sorafenib
- Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk OsteosarcomaRecruitingPhase 2Anna RaciborskaNCT07787429Written as Sorafenib
- Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Relapsed Hepatocellular CarcinomaNot yet recruitingPhase 3BeOne MedicinesNCT07836530Written as Sorafenib
- MRD-guided Maintenance Post-HCT: Gilteritini vs SorafenibRecruitingPhase 3The First Affiliated Hospital of Soochow UniversityNCT07463651Written as Sorafenib
- Combination of Toripalimab and JS004 Therapy for ccRCCRecruitingPhase 2Fudan UniversityNCT06690697Written as Sorafenib
- HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized TrialRecruitingPhase 2Sun Yat-sen UniversityNCT04135690Written as Sorafenib
- Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular CarcinomaActive, not recruitingPhase 3AstraZenecaNCT03298451Written as Sorafenib
- A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular CarcinomaCompletedPhase 3Bristol-Myers SquibbNCT04039607Written as Sorafenib
- Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedPhase 3Shanghai Junshi Bioscience Co., Ltd.NCT04723004Written as Sorafenib
- CXD101 in Immunotherapy-related Liver CancerActive, not recruitingPhase 2Stephen Chan LamNCT05873244Written as Lenvatinib and Sorafenib
- A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCCCompletedPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT04720716Written as Sorafenib
- An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver CancerCompletedPhase 1/2Bristol-Myers SquibbNCT01658878Written as Sorafenib
- Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer TherapyActive, not recruitingPhase 3ExelixisNCT03755791Written as Sorafenib
- Immunotherapy for Advanced Liver CancerSuspendedPhase 2/3Mirror Biologics, Inc.NCT05033522Written as Sorafenib
- A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedPhase 3BeiGeneNCT03412773Written as Sorafenib
- Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)Active, not recruitingPhase 2AbbVieNCT05822752Written as Sorafenib
- A Study to Assess the Pharmacokinetics of Sorafenib in Mesoporous Magnesium Carbonate (DPH001) Compared to Nexavar® (sorafenib) in Healthy VolunteersCompletedEarly Phase 1Disruptive PharmaNCT06797427Written as Nexavar (Sorafenib)
- Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma with PVTTTerminatedPhase 3Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT04709380Written as Sorafenib
- A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT04344158Written as Sorafenib Tosylate Tablets
- An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular CarcinomaCompletedPhase 3Bristol-Myers SquibbNCT02576509Written as Sorafenib
- A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT03764293Written as Sorafenib
Showing 20 of 55.
Codes
What other systems call Sorafenib · ClinicalTrials.gg INT006656
- MeSH (NLM) D000077157SorafenibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 9ZOQ3TZI87SORAFENIBConfirmed FDA, NLM, Wikidata
- RxNorm 495881Confirmed FDA, Wikidata
- Wikidata Q421136sorafenibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C61948SorafenibOne source FDA
- DrugBank DB00398One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077157 | Sorafenib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 9ZOQ3TZI87 | SORAFENIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 495881 | — | Confirmed FDA, Wikidata |
| Wikidata | Q421136 | sorafenib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C61948 | Sorafenib | One source FDA |
| DrugBank | DB00398 | — | One source Wikidata |
Also registered as bay-673472 (UNII 5XYK65KIGD) and sorafenib tosylate (UNII 5T62Q3B36J · RxNorm 597744).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.